Volume 5, Issue 5 (7-2007)                   IJRM 2007, 5(5): 183-186 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hosseini M –, Gharehkhani P, Sadeghi M. Association of inherited thrombophilia and antiphospholipid syndrome with severe preeclampsia. IJRM. 2007; 5 (5) :183-186
URL: http://journals.ssu.ac.ir/ijrmnew/article-1-89-en.html
1- Department of Gynecology and Obstetrics, Shaheed Beheshti University of Medical Sciences, Tehran, Iran , hoseiny339@yahoo.com
2- Department of Gynecology and Obstetrics, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
Abstract:   (1607 Views)
Background: Severe preeclampsia is a quite well-known entity with high incidence of both maternal and fetal morbidity and mortality. Although little is known about its etiology, inherited disorders of hemostasis and antiphospholipid syndrome have been postulated as common causes. The present study was conducted to evaluate the association of these two entities with preeclampsia in a group of Iranian patients.
Materials and Methods: A case-control study was performed on 26 parturients with severe preeclampsia and 26 healthy pregnant women who were matched according to the age, parity, gestational age and previous history of abortion. A 10cc blood sample was obtained and the following factors were measured: factor V Leiden, protein S, protein C, antithrombin III, anticardiolipin antibodies (IgM and IgG) and the presence of the lupus anticoagulant antibody.
Results: We have not found any significant difference in the values of factor V Leiden, antithrombin III, protein C, protein S, and anticardiolipin-IgG between preeclamptic (case) and non-preeclamptic (control) parturients. Meanwhile, lupus anticoagulant antibody was detected in one case and one control. However, anticardiolipin IgM was shown to be significantly higher in the preeclamptic patients. Severe preeclamptic parturients were 4.4 times more likely to develop elevated levels of IgM (OR=4.4, 95% CI=1.9-10, p<0.05).
Conclusion: Our results failed to reveal any significant association between preeclampsia and indices of inherited disorders of hemostasis, except for anticardiolipin IgM. Thus, routine screening of these indices are not recommended due to high expenses and shortness of reliability. 
Full-Text [PDF 98 kb]   (191 Downloads) |   |   Full-Text (HTML)  (105 Views)  
Type of Study: Original Article |

References
1. Cunninghum F, Gray, Gart Norman F, Leveno, Kenneth. J.Williams obstetrics. 21 ed. MCGRAW-HIL; 2002: 568-588.
2. Cherry and Merkatz's. Complication of pregnancy.5th Ed wayne R.Cohen; 2000: 208-210.
3. Abramovici Dorl, Sibai Baham. High Risk pregnancy 4th Edition. Joho.T.Queenan; 1999: 369-375.
4. Branch DW, Andres R, Digre KB, Rote NS, Scott JR. The association of antiphospholipid antibodies with severe pre-eclampsia. Obstet Gynecol 1989; 73: 541-545.
5. Allen JY, Tapia-Santiago C, Kutteh WH. Antiphospholipid antibodies in patients with pre-eclampsia. Am J Reprod Immunol 1996; 36: 81-85. [DOI:10.1111/j.1600-0897.1996.tb00143.x]
6. Alsulyman OM, Castro MA, Zuckerman E, MC Gehee W, Gooedwin TM. Preeclampsia and liver infarction in early pregnancy associated with the antiphospholipid syndrome. Obstet Gyncol 1996; 88(4 pt2): 644-646. [DOI:10.1016/0029-7844(96)00098-1]
7. Cetin M, Gucer S, Serin IS, Eser B, Toyyar M, Una LA. Activated protein C resistance in Turkish women with severe pre-eclampsia. Gynecol Obstet Invest 2001; 52:168-172. [DOI:10.1159/000052967]
8. Benedettoc, Marziol, salton L, Maula V, ChieppaG, Massobrio M. Factor V Leiden and factor II G 20210 A in preeclamspia and Hellp syndrome. Acta Obstect Gynecol Scand 2002; 81: 1095-1100. [DOI:10.1034/j.1600-0412.2002.811201.x]
9. Riyazi N, Leeda M, Devries JT, Huijgens PC, Van Geijn HP, Dekker GA. Low-molecular-weigh heparin in pregnant women with thrombophilia and a history of pre-eclampia or fetal growth restriction, a preliminary study. Obstect Gynaecol 2001; 97: 44-48.
10. Bernard N, Giguere Y. Genetics of pre-eclampsia: What are the challengens? Obstect Gynaecol 2003; 25: 578-585. [DOI:10.1016/S1701-2163(16)31017-9]
11. Girling J, de Swiet M. Inherited thrombophilia and pregnancy. Curr Opin Obtect Gynocol 1998; 10:135-144. [DOI:10.1097/00001703-199804000-00010]
12. Cavenagh JD, Colurin BT, Guide lines for the management of thrombophilia. Postgrde Med J 1996; 72:87-94. [DOI:10.1136/pgmj.72.844.87]
13. Kup ferminc MJ, Eldor A, steinman N, Many A, Bar-AM, Jaffa A, et al. Increased frequency of genetic thrombophilia in woman with complications of pregnancy. N EngL Med 1999; 340: 9-13. [DOI:10.1056/NEJM199901073400102]
14. Dekker GA, de Vires JI, Doelitezsch PM, Huijgens PC, Von Blomberg BM, Jacobs C, et al. underlying disorders associated with severe early-onset pre-eclapsia. AMJ Obstet Gynecol 1995; 173:1042-1048. [DOI:10.1016/0002-9378(95)91324-6]
15. Simmonds RE, Zoller B, Ireland H, Thompson E, de Frustos PG, Dahlback B. Genetic and phenotypic analysis of a large (122-member) protein S-deficient kindred proides an explanation for the familial coexistence of type I and type III plasma phenotypes. Blood 1997; 89:4364-4370.
16. Zoller B, Garcia de Frutos P, Dahlback B. Evaluation of the relationship between protein S and C 4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood 1995; 85:3524-3531.
17. Arais F, Romereo R, Joist H, Kravs FT. Thrombophilia a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in placenta, Matern Fetal Med 1998; 7:277-286. [DOI:10.3109/14767059809020459]
18. De Vries JI, Dekker GA, Huijgens PC, Jakobs C, Blombers BM, Van Geijn HP. Hyperhomocysteinemia and protein S deficiency in- Complicated pregnancies. Br J Obstet Gynaecol 1997; 104:1248-1254. [DOI:10.1111/j.1471-0528.1997.tb10970.x]
19. Van Pampus MG, Dekker GA, Wolf H, Huijgens PC, Koopman MM, Von Blomberg BM, et al, High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999; 180:1146-1150. [DOI:10.1016/S0002-9378(99)70608-3]
20. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The facto V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gnecol 1996; 175:902-905. [DOI:10.1016/S0002-9378(96)80022-6]
21. Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid antibodies and fetal death. Obstet Gnecol 1996; 87:489-493. [DOI:10.1016/0029-7844(95)00498-X]
22. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antiobodies. Hum Reprod 1995; 10-3301-3304. [DOI:10.1093/oxfordjournals.humrep.a135907]
23. Allen JY, Tapia-Santiago C, Kutteh WH. Annti-phospholipid antibodies in patients with preeclampsia. Am J Reprod Immuno 1996; 36:81-85. [DOI:10.1111/j.1600-0897.1996.tb00143.x]
24. Schei B,Ostensen M, Moen T, Jacobsen G, Bakketeig LS. Can maternal antiphospholipid antibodies predict the birth of a small-for-gestational age child? Acta Obs Gyn Scand 1995; 74:425-428. [DOI:10.3109/00016349509024403]
25. D'anna R, Scilipoti A, Leonardi J, Scuderi M, Jasonni VM, leonardi R. Anticardiolipin antibodies in preeclamsia and intrauterine growth restriction. Clin Exp Obstet Gynecol 1997; 24: 135-137.

Send email to the article author


© 2021 CC BY-NC 4.0 | International Journal of Reproductive BioMedicine

Designed & Developed by : Yektaweb